KR102557336B1 - 혈소판 조성물 및 치료제의 전달 방법 - Google Patents

혈소판 조성물 및 치료제의 전달 방법 Download PDF

Info

Publication number
KR102557336B1
KR102557336B1 KR1020197009451A KR20197009451A KR102557336B1 KR 102557336 B1 KR102557336 B1 KR 102557336B1 KR 1020197009451 A KR1020197009451 A KR 1020197009451A KR 20197009451 A KR20197009451 A KR 20197009451A KR 102557336 B1 KR102557336 B1 KR 102557336B1
Authority
KR
South Korea
Prior art keywords
apdl1
delete delete
platelets
platelet
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197009451A
Other languages
English (en)
Korean (ko)
Other versions
KR20190053206A (ko
Inventor
젠 구
차오 왕
Original Assignee
노쓰 캐롤라이나 스테이트 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노쓰 캐롤라이나 스테이트 유니버시티 filed Critical 노쓰 캐롤라이나 스테이트 유니버시티
Priority to KR1020237022734A priority Critical patent/KR20230109771A/ko
Publication of KR20190053206A publication Critical patent/KR20190053206A/ko
Application granted granted Critical
Publication of KR102557336B1 publication Critical patent/KR102557336B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Developmental Biology & Embryology (AREA)
KR1020197009451A 2016-09-13 2017-09-13 혈소판 조성물 및 치료제의 전달 방법 Active KR102557336B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237022734A KR20230109771A (ko) 2016-09-13 2017-09-13 혈소판 조성물 및 치료제의 전달 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662393839P 2016-09-13 2016-09-13
US62/393,839 2016-09-13
PCT/US2017/051376 WO2018053010A1 (en) 2016-09-13 2017-09-13 Platelet compositions and methods for the delivery of therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022734A Division KR20230109771A (ko) 2016-09-13 2017-09-13 혈소판 조성물 및 치료제의 전달 방법

Publications (2)

Publication Number Publication Date
KR20190053206A KR20190053206A (ko) 2019-05-17
KR102557336B1 true KR102557336B1 (ko) 2023-07-18

Family

ID=61620161

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197009451A Active KR102557336B1 (ko) 2016-09-13 2017-09-13 혈소판 조성물 및 치료제의 전달 방법
KR1020237022734A Ceased KR20230109771A (ko) 2016-09-13 2017-09-13 혈소판 조성물 및 치료제의 전달 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237022734A Ceased KR20230109771A (ko) 2016-09-13 2017-09-13 혈소판 조성물 및 치료제의 전달 방법

Country Status (8)

Country Link
US (1) US11730765B2 (enExample)
EP (1) EP3512554B1 (enExample)
JP (2) JP7262774B2 (enExample)
KR (2) KR102557336B1 (enExample)
CN (1) CN109890420B (enExample)
AU (1) AU2017327360A1 (enExample)
CA (1) CA3036693A1 (enExample)
WO (1) WO2018053010A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190388407A1 (en) 2017-02-12 2019-12-26 Aiviva Biopharma, Inc. Multikinase inhibitors of vegf and tfg beta and uses thereof
US11073462B2 (en) 2017-12-06 2021-07-27 Lightintegra Technology Inc. Non-activated platelet transfusion methods for enhancement of patient treatment outcomes
MX2020007071A (es) 2018-01-05 2020-11-11 Platelet Biogenesis Inc Composiciones y metodos para producir megacariocitos.
EP3773742A4 (en) * 2018-04-06 2022-03-16 North Carolina State University CELL SET-MEDIATED CHECKPOINT INHIBITOR DELIVERY FOR CANCER IMMUNOTHERAPY
EP3813853A4 (en) 2018-06-29 2022-04-06 Platelet Biogenesis, Inc. DELIVERY COMPOSITIONS AND METHODS OF USE
CA3109703C (en) 2018-08-15 2023-10-17 Aiviva Biopharma, Inc. Multi-kinase inhibitors of vegf and tgf beta and uses thereof
CN113164523A (zh) * 2018-10-10 2021-07-23 北卡罗莱纳州立大学 呈现pd-l1的血小板逆转新发1型糖尿病
US20230310504A1 (en) * 2020-07-01 2023-10-05 Cello Therapeutics, Inc. Platelet membrane coated nanoparticles and uses thereof
CN112826941A (zh) * 2020-08-14 2021-05-25 南京邮电大学 一种用于递送蛋白药物的磁性血小板复合物的制备方法
CN112891317A (zh) * 2021-02-05 2021-06-04 东南大学 一种血小板载药系统的制备方法
WO2024102818A1 (en) * 2022-11-09 2024-05-16 Wisconsin Alumni Research Foundation Combination tumor therapy with thrombosis initiation and platelet recruitment
CN116159149B (zh) * 2023-02-27 2024-11-15 上海中医药大学 一种基于血小板的免疫连接器的制备方法及应用
CN116603073A (zh) * 2023-05-29 2023-08-18 上海臻上医药科技有限公司 血小板负载的小分子药物制剂及其制备方法、和用途
CN118806929B (zh) * 2024-07-13 2026-02-06 江苏省肿瘤医院 一种复合型纳米硅球递药体系及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021706A2 (en) 2003-05-16 2005-03-10 University Of North Carolina At Chapel Hill Delivery of compounds with rehydrated blood cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
GB929405A (en) 1958-12-22 1963-06-19 Upjohn Co Processes for the encapsulation of particles
GB969808A (en) 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
JPH08109142A (ja) * 1994-08-16 1996-04-30 S R L:Kk 血小板薬物送達システム
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US20060141482A1 (en) 2004-12-23 2006-06-29 Awdalla Essam T Method and multicomponent conjugates for treating cancer
US20080317761A1 (en) * 2004-04-28 2008-12-25 The Trustees Of The University Of Pennsylvania Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
US20070178107A1 (en) * 2006-01-31 2007-08-02 Awdalla Essam T Method and means for treating solid tumors
AU2007243412A1 (en) * 2006-04-25 2007-11-08 Immune Disease Institute Inc. Targeted delivery to leukocytes using non-protein carriers
US8512697B2 (en) * 2007-05-16 2013-08-20 The University Of North Carolina At Chapel Hill Delivery of micro- and nanoparticles with blood platelets
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
EP4209510B1 (en) * 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US8673359B2 (en) 2010-07-08 2014-03-18 Brown University Nanoparticle compositions and methods for improved oral delivery of active agents
AU2013263076B2 (en) * 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN105102978B (zh) * 2013-02-02 2018-11-02 杜克大学 分离循环肿瘤细胞的方法
WO2016057898A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021706A2 (en) 2003-05-16 2005-03-10 University Of North Carolina At Chapel Hill Delivery of compounds with rehydrated blood cells

Also Published As

Publication number Publication date
KR20190053206A (ko) 2019-05-17
CA3036693A1 (en) 2018-03-22
US20190247438A1 (en) 2019-08-15
AU2017327360A1 (en) 2019-03-28
CN109890420A (zh) 2019-06-14
JP2023085470A (ja) 2023-06-20
EP3512554B1 (en) 2022-07-27
JP7262774B2 (ja) 2023-04-24
US11730765B2 (en) 2023-08-22
EP3512554A4 (en) 2020-06-17
KR20230109771A (ko) 2023-07-20
JP2019530673A (ja) 2019-10-24
JP7497087B2 (ja) 2024-06-10
WO2018053010A1 (en) 2018-03-22
EP3512554A1 (en) 2019-07-24
CN109890420B (zh) 2024-04-09

Similar Documents

Publication Publication Date Title
JP7497087B2 (ja) 治療剤送達のための血小板組成物及び方法
JP2022184935A (ja) 炎症の治療のための免疫修飾粒子
WO2017027760A1 (en) Platelet membrane-coated drug delivery system
US20130337066A1 (en) Membrane Encapsulated Nanoparticles and Method of Use
WO2019161192A1 (en) Engineered nanovesicles as checkpoint blockade for cancer immunotherapy
JP7470988B2 (ja) 生物応答性ヒドロゲルマトリックス及び使用方法
AU2015283343A1 (en) Purified therapeutic nanoparticles and preparation methods thereof
Shirali et al. Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival
US20210128725A1 (en) Cytotoxic lipid particles targeted to tumor-associated myeloid cells (tamcs) and synergized with radiation therapy for treating glioblastoma
Yin et al. Research advances in nanomedicine applied to the systemic treatment of colorectal cancer
US20240245721A1 (en) Double sided chimeric antigen receptor (car) engineered cell membrane based drug delivery systems
KR20150054543A (ko) 간 표적화 나노입자, 이의 제조방법 및 이를 포함하는 약학적 조성물
KR20130031557A (ko) 다기능성 나노입자를 포함하는 류마티스 관절염 치료용 조성물
EP3813884A1 (en) In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
Wang et al. Ultrasmall zwitterion-micelles coupled with anti-checkpoint antibody for overcoming glioma barriers to eliminate stem cells and amplify immunotherapy
HK40009575A (zh) 用於递送治疗剂的血小板组合物和方法
KR20240110161A (ko) 열 반응성 하이브리드 나노입자가 접합된 rmPD-1 단백질 복합체 및 이의 용도
EP4178988A1 (en) In situ thiol-maleimide crosslinked hydrogel for immune checkpoint blockade delivery
Wu et al. Platelet–Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy E cacy in Glioma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190402

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200825

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220817

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20230213

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230421

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230714

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230714

End annual number: 3

Start annual number: 1

PG1601 Publication of registration